#1 Clinical Trials Search in Europe

Faricimab

Faricimab is an innovative drug being studied in clinical trials for the treatment of various retinal diseases, including neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). This article explores the latest research on faricimab’s efficacy, safety, and potential benefits for patients with these vision-threatening conditions.

Table of Contents

What is Faricimab?

Faricimab is a new medication used to treat certain eye diseases. It’s also known by the brand names Vabysmo, RO6867461, and RG7716[1]. Faricimab is a type of drug called a bispecific antibody, which means it can target two different proteins in the body at the same time[2].

What Conditions Does Faricimab Treat?

Faricimab is used to treat several eye conditions that can cause vision loss:

  • Neovascular (wet) Age-related Macular Degeneration (nAMD): A condition where abnormal blood vessels grow in the back of the eye, potentially leading to vision loss[3].
  • Diabetic Macular Edema (DME): A complication of diabetes that causes swelling in the macula, the part of the eye responsible for detailed central vision[4].
  • Retinal Vein Occlusion (RVO): A condition where a vein in the retina becomes blocked, potentially leading to vision loss[5].
  • Non-Proliferative Diabetic Retinopathy (NPDR): An early stage of diabetic eye disease where blood vessels in the retina are damaged[6].

How Does Faricimab Work?

Faricimab works by targeting two proteins in the eye:

  1. Vascular Endothelial Growth Factor A (VEGF-A): This protein promotes the growth of abnormal blood vessels in the eye.
  2. Angiopoietin-2 (Ang-2): This protein is involved in inflammation and leakage from blood vessels.

By blocking both of these proteins, Faricimab aims to reduce abnormal blood vessel growth, decrease inflammation, and prevent fluid leakage in the eye[2]. This dual action is what makes Faricimab unique compared to older treatments that only target VEGF-A.

How is Faricimab Administered?

Faricimab is given as an injection directly into the eye (intravitreal injection). The typical dose is 6 milligrams (mg) in 0.05 milliliters (mL) of solution[1]. The injection is usually performed by an eye doctor in their office. Before the injection, the eye is numbed with drops and cleaned to prevent infection.

The frequency of injections can vary depending on the patient’s condition and response to treatment. Some patients may receive injections every 4 weeks initially, while others may be able to go longer between treatments[4].

How Effective is Faricimab?

Clinical trials have shown that Faricimab can be effective in treating nAMD and DME. Some key findings include:

  • Improved vision: Many patients experience improvements in their visual acuity (sharpness of vision)[1].
  • Reduced retinal thickness: Faricimab can help decrease swelling in the retina[7].
  • Longer treatment intervals: Some patients may be able to go longer between injections compared to older treatments, potentially reducing the burden of frequent doctor visits[8].

Safety and Side Effects

Like all medications, Faricimab can have side effects. Common side effects related to the injection procedure may include:

  • Eye pain or discomfort
  • Redness in the eye
  • Floaters (small dark spots in vision)

More serious side effects are rare but can include eye infections or inflammation. Your doctor will monitor you closely for any potential complications[1].

Ongoing Research

Researchers are continuing to study Faricimab to better understand its long-term effects and potential uses. Some areas of ongoing research include:

  • Comparing Faricimab to other treatments for eye diseases[2].
  • Studying Faricimab in patients who haven’t responded well to other treatments[9].
  • Investigating the use of Faricimab in other eye conditions[6].
  • Evaluating different dosing schedules to find the most effective and convenient treatment regimens[4].

As research continues, we may learn even more about how Faricimab can help patients with various eye conditions.

Aspect Details
Drug Name Faricimab (also known as VABYSMO™, RO6867461, RG7716)
Mechanism of Action Bispecific antibody targeting VEGF-A and Ang-2
Conditions Studied Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Diabetic Retinopathy
Administration Intravitreal injection, typically 6 mg dose
Treatment Intervals Ranging from every 4 weeks to potentially every 16-24 weeks
Primary Outcomes Changes in Best Corrected Visual Acuity (BCVA), Central Subfield Thickness (CST), retinal fluid presence
Secondary Outcomes Treatment durability, changes in diabetic retinopathy severity, patient-reported outcomes
Safety Monitoring Ocular and non-ocular adverse events, development of anti-drug antibodies
Potential Advantages Extended treatment intervals, dual-pathway inhibition for potentially stronger and longer-lasting efficacy
Study Designs Phase II to IV trials, including randomized controlled trials and real-world observational studies

FAQ

  • What is faricimab and how does it work? Faricimab is a bispecific antibody that targets both VEGF-A and Ang-2 proteins. It works by inhibiting abnormal blood vessel growth and reducing fluid leakage in the retina, potentially offering longer-lasting effects compared to existing treatments.
  • What conditions is faricimab being studied for? Faricimab is primarily being investigated for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Some studies are also looking at its effects on diabetic retinopathy.
  • How is faricimab administered? Faricimab is given as an intravitreal injection, meaning it is injected directly into the eye. The typical dose is 6 mg, and the frequency of injections varies depending on the study protocol and individual patient needs.
  • What are the potential benefits of faricimab over existing treatments? Clinical trials suggest that faricimab may offer longer treatment intervals between injections, potentially reducing the treatment burden for patients. Some studies are exploring dosing intervals of up to 16 or even 24 weeks.
  • Are there any known side effects of faricimab? As with any medication, faricimab can have side effects. Clinical trials are monitoring for both ocular (eye-related) and non-ocular adverse events. The full safety profile is still being established through ongoing research.

Ongoing Clinical Trials on Faricimab

  • A Study Testing How Well Faricimab Works in Patients with Subretinal Hyperreflective Material Associated with Neovascular Membranes in the Eye

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of Faricimab treatment to improve vision in patients with diabetic macular edema using adaptive optics imaging

    Recruiting

    1 1 1 1
    Investigated drugs:
    Germany

  • Study on the Effects of Faricimab for Caucasian Patients with Polypoidal Choroidal Vasculopathy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Italy Portugal Spain

  • Study of Faricimab Treatment Given Every 24 Weeks in Patients with Age-Related Macular Degeneration

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Italy Spain

  • Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Italy Poland Spain

  • Study on Faricimab and Aflibercept for Patients with Neovascular Age-Related Macular Degeneration Receiving Frequent Aflibercept Treatment

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria

  • Study on Faricimab for Patients with Neovascular Age-Related Macular Degeneration Who Have Not Received Prior Treatment

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

Glossary

  • Neovascular Age-related Macular Degeneration (nAMD): A condition where abnormal blood vessels grow under the retina, potentially leading to vision loss if left untreated.
  • Diabetic Macular Edema (DME): A complication of diabetes where fluid accumulates in the macula, the central part of the retina, causing vision problems.
  • Intravitreal Injection: A procedure where medication is injected directly into the vitreous, the jelly-like substance inside the eye.
  • VEGF-A: Vascular Endothelial Growth Factor A, a protein that stimulates the growth of blood vessels and is a target of many eye treatments.
  • Ang-2: Angiopoietin-2, another protein involved in blood vessel formation and a target of faricimab.
  • Best Corrected Visual Acuity (BCVA): A measure of the sharpness of vision when wearing the best possible corrective lenses.
  • Central Subfield Thickness (CST): A measurement of the thickness of the central part of the retina, often used to assess the effectiveness of treatments for retinal conditions.
  • Treat and Extend (T&E): A treatment approach where the interval between injections is gradually increased if the condition remains stable.
  • Early Treatment Diabetic Retinopathy Study (ETDRS) Chart: A standardized eye chart used to measure visual acuity in clinical trials and eye care.
  • Optical Coherence Tomography (OCT): An imaging technique that provides detailed cross-sectional images of the retina, used to diagnose and monitor eye conditions.

References

  1. https://clinicaltrials.gov/study/NCT05224102
  2. https://clinicaltrials.gov/study/NCT05610319
  3. https://clinicaltrials.gov/study/NCT06680817
  4. https://clinicaltrials.gov/study/NCT05610488
  5. https://clinicaltrials.gov/study/NCT06572553
  6. https://clinicaltrials.gov/study/NCT05681884
  7. https://clinicaltrials.gov/study/NCT04597918
  8. https://clinicaltrials.gov/study/NCT06271330
  9. https://clinicaltrials.gov/study/NCT06231121